Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
Scientists organize millions of proteins by shape, as predicted by AI, revealing 700,000 new families and some shapes unique ...
On Nov. 27, after the launch of the Soyuz 2.1a rocket with the Soyuz MS-28 crew and spacecraft, an accident occurred on the launch pad at Site 31/6 at the Baikonur Cosmodrome. The launch itself was ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...
Two-photon imaging and ocular dominance mapping. A. Optical windows for imaging of two macaques. Green crosses indicate the regions for viral vector injections, and yell ...
Background Predicting progression to aortic valve replacement (AVR) in moderate aortic stenosis (AS) is challenging. This ...
Thinking about a career in semiconductors? It’s a field that’s constantly changing and super important for all ...
One of the most detailed 3D maps of how the human chromosomes are organized and folded within a cell's nucleus is published ...
Learn how an Access Fabric can continuously decide who can access what, from where, and under what conditions—in real time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback